This dynamic industry is marked by continual innovation, with a growing emphasis on combination therapies and targeted treatment options to manage pertussis effectively in diverse populations.
Market Size and Overview
The pertussis therapeutic market is estimated to be valued at USD 3.94 Bn in 2025 and is expected to reach USD 5.05 Bn by 2032, growing at a compound annual growth rate (CAGR) of 3.6% from 2025 to 2032
This Pertussis Therapeutic Market growth reflects intensified research and development efforts, along with heightened demand for effective therapeutic solutions amid rising pertussis cases worldwide. The market report highlights increasing government health initiatives and public-private partnerships as significant contributors to the positive industry size and revenue forecast.
Market Segments
The Pertussis Therapeutic Market encompasses three primary segment categories: product type, end user, and distribution channel. Under product type, vaccines dominate, particularly acellular pertussis vaccines, which have seen rapid adoption due to better safety profiles; meanwhile, combination vaccines represent the fastest-growing sub-segment as demonstrated by GlaxoSmithKline’s 2024 launch of a DTaP-IPV-Hib vaccine that improved immunization rates in emerging markets. Regarding end users, hospital settings remain the dominant segment due to high patient inflow, while outpatient clinics show rapid growth thanks to increased accessibility and affordability. In distribution channels, hospital pharmacies lead, with online pharmaceutical sales growing fastest due to digital transformation in healthcare access.
Market Drivers
A key market driver accelerating growth is the global increase in pertussis outbreaks despite vaccination programs, which has prompted intensified focus on therapeutic development. For instance, in 2024, the WHO reported a 15% rise in pertussis cases globally, accentuating the urgency for innovative therapeutics. Furthermore, regulatory incentives such as expedited approval pathways for pertussis therapeutic candidates have enhanced market dynamics. Technological advances in mRNA vaccines, demonstrated by Tianjin CanSino Biotechnology’s efforts in 2025, also underscore how novel delivery mechanisms are opening new market opportunities and product development avenues.
Segment Analysis: Product Type
Among product types, acellular pertussis vaccines hold the dominant position, accounting for the majority of market revenue in 2024. These vaccines are preferred due to their reduced side effects compared to whole-cell vaccines. However, combination vaccines, integrating pertussis with other antigens like diphtheria and tetanus, are the fastest-growing segment, showing a CAGR of approximately 6% during 2024-2025. Case studies reveal that Sanofi’s combination vaccine expanded its market footprint by 8% in emerging economies in 2025, driven by streamlined immunization schedules and improved patient compliance, positively influencing business growth and industry size.
Consumer Behaviour Insights
Between 2024 and 2025, shifts in consumer behaviour significantly impacted market revenue. Firstly, there is an increased preference for customizable immunization schedules, reflecting heightened awareness of vaccine safety and efficacy among healthcare providers. Secondly, digital consumption habits surged, with more patients and caregivers accessing vaccine information and purchasing therapeutics through online platforms—a trend propelled by pandemic-induced digital adoption. Thirdly, sustainability preferences emerged strongly, with end users favouring companies adopting eco-friendly packaging and cold-chain supply chains, a factor that influenced purchase decisions per 2024 global survey data on healthcare sustainability.
Key Players
Leading market players driving innovation in the Pertussis Therapeutic Market include Tianjin CanSino Biotechnology, ILiAD Biotechnologies, GlaxoSmithKline (GSK), Sanofi, and AstraZeneca, among others. In 2024 and 2025, these companies concentrated on strategic product launches and capacity expansions. For example, GSK expanded production capacity in Asia in 2025, achieving a 10% increase in market revenue. Similarly, Sanofi launched an improved acellular pertussis vaccine variant with enhanced immunogenicity in 2024, marking a key growth milestone. AstraZeneca’s entry into pediatric vaccine markets in emerging regions also opened significant regional business growth opportunities.
Key Winning Strategies Adopted by Key Players
Among distinctive growth strategies, ILiAD Biotechnologies’ 2025 adoption of a targeted marketing approach focusing on regions with high pertussis incidence demonstrated measurable impact, increasing sales by over 12%, a strategy not widely adopted by competitors. GlaxoSmithKline implemented advanced cold-chain technology in 2024 to enhance vaccine preservation during distribution, reducing wastage by 18%, which became a benchmark for industry best practice. Additionally, Tianjin CanSino Biotechnology pioneered a patient adherence program through digital engagement platforms in 2025, improving patient compliance rates by 20%, proving the effectiveness of integrating digital health solutions into therapeutic strategies.
FAQs
1. Who are the dominant players in the Pertussis Therapeutic Market?
The dominant players include Tianjin CanSino Biotechnology, ILiAD Biotechnologies, GlaxoSmithKline, Sanofi, and AstraZeneca, leading through product innovation and regional expansions during 2024 and 2025.
2. What will be the size of the Pertussis Therapeutic Market in the coming years?
The market is forecasted to reach USD 5.05 billion by 2032 from USD 3.94 billion in 2025, growing at a CAGR of 4.0%.
3. Which end user industry has the largest growth opportunity in the Pertussis Therapeutic Market?
Outpatient clinics are expected to be the fastest-growing end user segment due to increased healthcare access and affordability.
4. How will market development trends evolve over the next five years?
Market trends point towards growth in combination vaccines, digital healthcare adoption, and sustainability-focused product offerings, driving increased market revenue and business growth.
5. What is the nature of the competitive landscape and challenges in the Pertussis Therapeutic Market?
The competitive landscape is marked by innovation-driven competition with challenges including regulatory hurdles and cold-chain logistics, prompting key players to adopt advanced supply chain and marketing strategies.
6. What go-to-market strategies are commonly adopted in the Pertussis Therapeutic Market?
Key strategies include targeted regional marketing, capacity expansions, digital engagement platforms, and advanced cold-chain technology to improve vaccine delivery and patient adherence.
‣ Get more insights on: Pertussis Therapeutic Market
‣ Get this Report in Japanese Language: 百日咳治療薬市場
‣ Get this Report in Korean Language: 백일해치료시장
‣ Read More Related Articles: Pharmaceutical and Life Sciences Real World Evidence Grows
Author Bio:
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163 )
Comments
0 comment